Heart failure means the heart muscle cannot pump blood as well as the body needs, often after a heart attack or because of long-term high blood pressure or cardiomyopathy. Heart muscle cells barely regenerate, so for two decades researchers have tested whether stem or precursor cells could repair damaged muscle or reduce harmful inflammation.
AT A GLANCE · HEART FAILURE
| Evidence level | Promising – in clinical trials |
|---|---|
| Approved stem cell treatment? | No stem cell product is approved for heart failure by the US FDA or the European EMA. |
| Typical private price | $10,000 – $50,000 (indicative) |
| Recruiting trials | 11 listed on ClinicalTrials.gov (4 October 2026) |
| Last reviewed | October 2026 |
Does stem cell therapy work for heart failure?
Heart cell therapy has been studied in thousands of patients, with mixed results. The largest trial so far, DREAM-HF, injected donor mesenchymal precursor cells directly into the heart muscle of 537 people with chronic heart failure and followed them for about 30 months (published in JACC, 2023). It missed its main goal: the cells did not reduce repeat hospital admissions for heart failure compared with a sham procedure. 6% vs 13%) and fewer cardiac deaths in people with milder symptoms or high inflammation, but these need confirming in a new trial.
Earlier bone marrow cell trials were largely disappointing; the BAMI trial (2020) in heart attack patients found no survival benefit. The field was also set back in 2018 when Harvard and Brigham and Women’s Hospital called for 31 papers on so-called cardiac stem cells to be retracted. Overall, cell therapy may help some patients, but it is not yet proven.
Is any stem cell treatment approved for heart failure?
No stem cell product is approved for heart failure by the US FDA or the European EMA. Japan gave conditional, time-limited approval in early 2026 to heart muscle cell sheets made from iPS cells for severe heart failure due to ischaemic cardiomyopathy, while data continue to be collected; an earlier conditionally approved muscle-cell sheet lost its approval in 2024 after failing to show enough benefit. South Korea approved a bone marrow-derived MSC product for heart attack recovery in 2011, but not for chronic heart failure.
What private clinics offer — and how it compares
Private clinics sell IV infusions of fat, bone marrow or umbilical cord cells promising stronger hearts, higher ejection fraction and more energy. IV-infused cells mostly lodge in the lungs rather than the heart, and the rigorous trials that inject cells directly into heart muscle have not proven benefit, so these clinic claims run well ahead of the evidence.
Proven treatments to discuss first
Before paying for an experimental option, make sure you have explored the established treatments for heart failure with your doctor:
- Guideline medicines for reduced ejection fraction: ARNI or ACE inhibitor/ARB, beta-blocker, mineralocorticoid antagonist and SGLT2 inhibitor
- Diuretics to control fluid build-up
- Implantable devices such as defibrillators (ICD) or cardiac resynchronisation therapy (CRT) when indicated
- Cardiac rehabilitation, salt and fluid guidance and regular monitoring
- Treating causes such as blocked arteries, valve disease or high blood pressure
- Left ventricular assist devices or heart transplant for advanced heart failure
How much does stem cell therapy for heart failure cost?
Private clinics typically quote $10,000 to $50,000. Clinic prices for cardiac ‘stem cell’ packages are not publicly standardised; commonly advertised totals are in the tens of thousands of dollars with travel. Research trials such as DREAM-HF do not charge participants, and insurance does not cover clinic treatments. Compare prices by country in our cost guide and location guides, and check insurance coverage.
Risks and side effects
- Heart rhythm problems, heart attack or perforation during catheter injection into the heart
- Clots, stroke or lung embolism from IV-infused cells
- Infection or contamination from unregulated cell products
- Dangerous fluid overload or medicine changes when away from your heart team
- Stopping proven heart failure medicines, which can be life-threatening
Recruiting clinical trials for heart failure
On 4 October 2026, ClinicalTrials.gov listed 11 recruiting or soon-to-recruit stem cell studies for this condition, 2 with sites in the United States. Here are up to eight, latest-stage first:
See all matching studies on ClinicalTrials.gov. A listing is not an endorsement: registration does not mean a study is safe or effective, and genuine trials rarely charge you for the experimental treatment. Ask the study team about costs, placebo groups and follow-up before you enrol. See our clinical trials hub.
Questions to ask before you agree to treatment
- How do your results compare with the DREAM-HF trial, which did not reduce heart failure hospitalisations?
- Are cells injected into the heart by a cardiologist or given by IV, and where do the cells end up?
- Is this a registered trial with an FDA IND number and independent ethics oversight?
- What monitoring will there be for heart rhythm problems, and who handles complications after I return home?
Before You Pay: The Stem Cell Clinic Checklist
- 20 questions every legitimate clinic should answer in writing
- A red-flag scorecard to spot unregulated marketing
- Realistic 2026 cost ranges: US, Mexico, Panama & Europe
- How to find a registered clinical trial
Red flags to watch for
- Advice to stop or cut back your heart failure medicines
- Claims that an IV drip will rebuild heart muscle or raise ejection fraction
- No cardiologist involved, or no plan to share results with your heart team
Stem cell therapy for heart failure: FAQs
Does stem cell therapy work for heart failure?
It is not proven. The large DREAM-HF trial in 537 patients did not reduce heart failure hospitalisations, although it hinted at fewer heart attacks, strokes and cardiac deaths in some groups. A new confirmatory trial is needed.
What did the DREAM-HF trial find?
Published in 2023, DREAM-HF found that donor precursor cells injected into the heart did not meet the main goal of fewer heart failure admissions. Secondary results showed fewer non-fatal heart attacks and strokes and fewer cardiac deaths in people with milder symptoms or high inflammation.
Is stem cell therapy FDA approved for heart failure?
No. The FDA has not approved any stem cell product for heart failure. Japan has granted a conditional, time-limited approval for iPS-derived heart cell sheets in severe ischaemic heart failure, with further data still required.
How much does stem cell therapy for heart failure cost?
Private clinic packages often cost tens of thousands of dollars, plus travel. Legitimate clinical trials do not charge patients for the cells.
Is stem cell therapy for heart failure covered by insurance?
No. Insurers do not cover unproven cell treatments for heart failure. Guideline medicines, devices and cardiac rehabilitation are usually covered.
Related guides
- Stem cell therapy for hair loss
- Stem cell therapy for macular degeneration
- Stem cell therapy for COPD
- Stem cell therapy for kidney disease
- All conditions · Types of stem cell treatment · Clinical trials hub
Sources
- Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure (JACC, 2023)
- Trial of cell therapy for HF misses primary endpoint, but signals a path forward (TCTMD)
- The BAMI trial: bone marrow cells and mortality in acute myocardial infarction (European Heart Journal, 2020)
- Harvard and the Brigham call for 31 retractions of cardiac stem cell research (STAT, 2018)
- Japan’s conditional/time-limited approval system: the rise and fall of autologous skeletal myoblast sheets (Clinical Pharmacology & Therapeutics)
- Japan authorizes the first iPSC-based cell therapies (BioInformant, 2026)
Last reviewed October 2026. For general information only — not medical advice. We do not endorse any clinic or product. Always consult a qualified, licensed healthcare professional. See our medical disclaimer and editorial policy.